LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo. Liu Y, Lai M, Li S, Wang Y, et al. Cancer Sci 2022;113:709-720.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Liu Y, Lai M, Li S, Wang Y, et al. LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo. Cancer Sci 2022;113:709-720.
PMID: 34855271